RxDoctor Payments Data

Eduard Docu, MD

Family Medicine · Savannah, GANPI 1891777355

Payments from drug & device makers

$529in general payments, 2019–2025

Across 30 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$250
  • Esperion Therapeutics, Inc.$69
  • Takeda Pharmaceuticals U.S.A., Inc.$56
  • Lilly USA, LLC$44
  • Bayer$27
  • Amarin Pharma, Inc.$18
  • plus $65 from 5 others

What the payments were for

  • Food & beverage$48692%
  • Education$428%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$529 in reported general payments places this provider in the 45th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$192,359
Medicare patients
367
Services billed
2,175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide107$161,889
EliquisApixaban95$133,694
FarxigaDapagliflozin Propanediol89$114,014
LinzessLinaclotide68$77,420
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$74,950
MounjaroTirzepatide53$73,983
JardianceEmpagliflozin53$65,669
JanuviaSitagliptin Phosphate46$44,821
MyrbetriqMirabegron41$39,909
Tresiba Flextouch U-100Insulin Degludec30$18,161
TrulicityDulaglutide12$12,485
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$7,395
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$5,979
Rosuvastatin Calcium544$5,446
Dexlansoprazole DrDexlansoprazole13$4,956

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$250$161,889107 claims
PfizerEliquis$15$133,69495 claims
AstraZenecaFarxiga$11$114,01489 claims
Lilly USA, LLCMounjaro, Trulicity$44$86,46865 claims
GSKTrelegy Ellipta, Anoro Ellipta$12$80,92958 claims
AbbVieLinzess$11$77,42068 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →